BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 8753752)

  • 1. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy.
    Wright GL; Grob BM; Haley C; Grossman K; Newhall K; Petrylak D; Troyer J; Konchuba A; Schellhammer PF; Moriarty R
    Urology; 1996 Aug; 48(2):326-34. PubMed ID: 8753752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.
    Denmeade SR; Sokoll LJ; Dalrymple S; Rosen DM; Gady AM; Bruzek D; Ricklis RM; Isaacs JT
    Prostate; 2003 Mar; 54(4):249-57. PubMed ID: 12539223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations of prostate biomarker expression and testosterone utilization in human LNCaP prostatic carcinoma cells by garlic-derived S-allylmercaptocysteine.
    Pinto JT; Qiao C; Xing J; Suffoletto BP; Schubert KB; Rivlin RS; Huryk RF; Bacich DJ; Heston WD
    Prostate; 2000 Dec; 45(4):304-14. PubMed ID: 11102955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel regulation of PSMA and PSA expression by Q640X AR in 22Rv1 and LNCaP prostate cancer cells.
    Ben Jemaa A; Sallami S; Céraline J; Oueslati R
    Cell Biol Int; 2013 May; 37(5):464-70. PubMed ID: 23418075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short term neoadjuvant androgen deprivation therapy does not affect prostate specific membrane antigen expression in prostate tissues.
    Chang SS; Reuter VE; Heston WD; Hutchinson B; Grauer LS; Gaudin PB
    Cancer; 2000 Jan; 88(2):407-15. PubMed ID: 10640975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of androgen deprivation therapy on PSMA expression and PSMA-ligand PET imaging of prostate cancer patients.
    Vaz S; Hadaschik B; Gabriel M; Herrmann K; Eiber M; Costa D
    Eur J Nucl Med Mol Imaging; 2020 Jan; 47(1):9-15. PubMed ID: 31654093
    [No Abstract]   [Full Text] [Related]  

  • 7. Antihormone treatment differentially regulates PSA secretion, PSMA expression and
    Mathy CS; Mayr T; Kürpig S; Meisenheimer M; Dolscheid-Pommerich RC; Stoffel-Wagner B; Kristiansen G; Essler M; Muders MH; Bundschuh RA
    J Cancer Res Clin Oncol; 2021 Jun; 147(6):1733-1743. PubMed ID: 33760944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Androgen Receptor Activity on Prostate-Specific Membrane Antigen Expression in Prostate Cancer Cells.
    Sommer U; Siciliano T; Ebersbach C; Beier AK; Stope MB; Jöhrens K; Baretton GB; Borkowetz A; Thomas C; Erb HHH
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35162969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pilot study of prostate-specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer.
    Paller CJ; Piana D; Eshleman JR; Riel S; Denmeade SR; Isaacsson Velho P; Rowe SP; Pomper MG; Antonarakis ES; Luo J; Eisenberger MA
    Prostate; 2019 Oct; 79(14):1597-1603. PubMed ID: 31361358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological upregulation of prostate-specific membrane antigen (PSMA) expression in prostate cancer cells.
    Kranzbühler B; Salemi S; Umbricht CA; Müller C; Burger IA; Sulser T; Eberli D
    Prostate; 2018 Jul; 78(10):758-765. PubMed ID: 29633296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upregulation of prostate specific membrane antigen/folate hydrolase transcription by an enhancer.
    Noss KR; Wolfe SA; Grimes SR
    Gene; 2002 Feb; 285(1-2):247-56. PubMed ID: 12039052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concentration-dependent effects of dutasteride on prostate-specific membrane antigen (PSMA) expression and uptake of
    Kranzbühler B; Salemi S; Umbricht CA; Deberle LM; Müller C; Burger IA; Hermanns T; Sulser T; Eberli D
    Prostate; 2019 Sep; 79(12):1450-1456. PubMed ID: 31233227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy.
    Kuroda K; Liu H; Kim S; Guo M; Navarro V; Bander NH
    Prostate; 2009 Oct; 69(14):1579-85. PubMed ID: 19575420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-expression and impact of prostate specific membrane antigen and prostate specific antigen in prostatic pathologies.
    Ben Jemaa A; Bouraoui Y; Sallami S; Banasr A; Ben Rais N; Ouertani L; Nouira Y; Horchani A; Oueslati R
    J Exp Clin Cancer Res; 2010 Dec; 29(1):171. PubMed ID: 21189143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer.
    Murga JD; Moorji SM; Han AQ; Magargal WW; DiPippo VA; Olson WC
    Prostate; 2015 Feb; 75(3):242-54. PubMed ID: 25327687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of the prostate-specific membrane antigen.
    Israeli RS; Powell CT; Corr JG; Fair WR; Heston WD
    Cancer Res; 1994 Apr; 54(7):1807-11. PubMed ID: 7511053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines.
    Sokoloff MH; Tso CL; Kaboo R; Taneja S; Pang S; deKernion JB; Belldegrun AS
    Cancer; 1996 May; 77(9):1862-72. PubMed ID: 8646686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormonal regulation of prostate-specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line, LNCaP.
    Montgomery BT; Young CY; Bilhartz DL; Andrews PE; Prescott JL; Thompson NF; Tindall DJ
    Prostate; 1992; 21(1):63-73. PubMed ID: 1379363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids.
    Troyer JK; Beckett ML; Wright GL
    Int J Cancer; 1995 Sep; 62(5):552-8. PubMed ID: 7665226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined androgen blockade therapy can convert RT-PCR detection of prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) transcripts from positive to negative in the peripheral blood of patients with clinically localized prostate cancer and increase biochemical failure-free survival after curative therapy.
    Lembessis P; Msaouel P; Halapas A; Sourla A; Panteleakou Z; Pissimissis N; Milathianakis C; Bogdanos J; Papaioannou A; Maragoudakis E; Dardoufas C; Dimopoulos T; Koutsilieris M
    Clin Chem Lab Med; 2007; 45(11):1488-94. PubMed ID: 17924845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.